Christopher Poole

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

Annie Young, Andrea Marshall, Jenny Thirlwall et al. · Journal of Clinical Oncology · 2018 · 1.3K citations · Full text

Vte Recurrence, Pathology, Pharmacotherapy +21

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Amit M. Oza, David Cibula, Ana Oaknin Benzaquen et al. · The Lancet Oncology · 2014 · 540 citations

Medicine, Randomised Phase 2, Gynecology +6

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

Richard Gray, Daniel Rea, Kelly Handley et al. · Journal of Clinical Oncology · 2013 · 446 citations

Breast Oncology, Cancer Management, Epidemiology Of Cancer +17

First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial

Mothaffar F. Rimawi, Jean-­Marc Ferrero, Juan de la Haba-Rodríguez et al. · Journal of Clinical Oncology · 2018 · 213 citations

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

John M.S. Bartlett, Jane Bayani, Andrea Marshall et al. · JNCI Journal of the National Cancer Institute · 2016 · 210 citations · Full text